Healthcare
Hong Kong biotech IPOs: Capital injection
The move to allow zero-revenue biotech companies to list in Hong Kong has spurred investor interest in healthcare. But valuations are high and success in this capital-intensive space is by no means guaranteed
Qiming leads $37m round for China's Alpha Biopharma
China’s Qiming Venture Partners has led a $37 million Series A investment in domestic biopharmaceutical start-up Alpha Biopharma.
CITIC Capital makes $3.6b bid for China Biologic Products
CITIC Capital has submitted a take-private bid for China Biologic Products that values the US-listed biopharmaceutical developer at approximately $3.65 billion.
SeaLink leads $29m round for Indian children’s hospital
SeaLink Capital Partners has led a INR2 billion ($29 million) investment in Indian maternal and pediatric hospital chain Surya Children’s Medicare, providing an exit for OrbiMed Advisors.
Shunwei, DCM lead $65m round for China's Yaoshibang
Chinese B2B pharmaceutical trading and education platform Yaoshibang has received RMB420 million ($65 million) in Series C funding across two tranches.
Australia-listed Sirtex accepts CDH's $1.4b buyout offer
Australian medical device manufacturer Sirtex Medical has accepted a A$1.9 billion ($1.4 billion) buyout offer from China’s CDH Investments, pulling the plug on an earlier agreement with US-listed Varian Medical Systems.
Japan demographics: New normal, new entries
Private equity investors see potential for growth in Japan’s demographic contractions. Countercyclical and tangential consolidation strategies are the preferred gambits in a churning macro environment
Capital Group, GL buy stake in Chinese hospital operator
Capital Group Private Markets (CGPM) has joined GP Capital to invest in Jinxin Healthcare, the maternity care division of Chinese hospital operator Chengdu Jinxin Healthcare Investment Management Group (Jinxin Group).
Pivotal China seeds Sino-US cancer drug developer
Pivotal BioVenture Partners China, an investment platform of Hong Kong conglomerate Nan Fung Group, has led a $16.5 million seed round for Sino-US cancer drug developer Oncologie.
Hua Medicine files for HK IPO under biotech fastrack
Hua Medicine, a Chinese drug developer player that simultaneously closed its Series D and E funding rounds in March, has become the second company to file for a Hong Kong IPO under rules that allow zero revenue biotech businesses to go public.
Drug developer Just China raises $35m
Hangzhou Just Biotherapeutics (Just China), the Chinese joint venture of US drug developer Just Biotherapeutics, has received $35 million in Series B-plus funding led by Hillhouse Capital.
Fund focus: Pivotal’s urge to incubate
Nan Fung Group has established Pivotal Bioventure Partners China to build a concentrated portfolio of high-quality life science assets and nurture them from inception to exit
Goldman leads $31m round for India hospital
Goldman Sachs has led a $31 million Series A round for Indian cancer care provider Cytecare Hospitals as part of a global oncology investment strategy.
Hony sells Chinese hospital to Hong Kong-listed platform
Hony Capital has agreed to sell three private hospitals in Zhejiang province to Hospital Corporation of China (HCC), a Hong Kong-listed platform it established several years ago, for RMB630 million ($98 million).
India's Fortis reopens bidding for hospital business
Indian healthcare service provider Fortis Healthcare (FHL) has reopened bidding for its hospital operation and invited offers from several potential investors, including TPG Capital-backed Manipal Hospital Enterprises (MHEPL).
Singapore biotech player gets $20m Series A
A group of VCs including Yashang Capital and Westlake Ventures have backed a $20 million Series A funding round for Singaporean biotech developer Lion TCR.
CDH leads round for Chinese DNA-based drug developer
CDH Investments has led a RMB250 million ($39 million) Series B round of funding for HitGen, a Chinese biotech company that develops drugs based on the synthesis and screening of DNA fragments.
Korean drug developer raises $21.8m Series B round
TiumBio, a South Korean drug developer working on treatments for cancer, diabetes and hemophilia, has secured KRW23.5 billion ($21.8 million) in Series B funding.
Pivotal raises $150m for China life sciences fund
Pivotal Bioventure Partners China, an investment platform of Hong Kong conglomerate Nan Fung Group, has raised $150 million for a fund that will incubate Chinese life science start-ups.
Brii Biosciences gets $260m for China expansion
A group of VCs, including Sequoia Capital, have committed $260 million to Brii Biosciences, a China and US-based healthcare start-up executing a number of China-focused growth initiatives.
Chinese VCs join $300m round for US, Hong Kong-based Grail
Ally Bridge Group, Hillhouse Capital and 6 Dimensions Capital have co-led a $300 million Series C round for Grail, a biotechnology development firm based in Hong Kong and the US.
Hong Kong technology IPOs: Size matters
Hong Kong has altered its IPO regime to attract tech companies with unorthodox shareholding structures and biotech start-ups with no revenue. But only certain businesses are welcome to apply
Legend hits $156m first close on renminbi healthcare fund
Legend Capital has reached a first close of RMB1 billion ($156 million) on its second dedicated healthcare fund. A US dollar-denominated vehicle – also the VC firm’s second for the sector – is scheduled for launch in the third quarter.
Australia's Healthscope rejects PE takeover bids
Australian hospital operator Healthscope has rejected buyout offers from Brookfield Asset Management and a consortium led by BGH Capital that valued the company at A$4.4 billion ($3.3 billion) and A$4.1 billion, respectively.